Maximizing the Public Health Benefits of Opioid Settlements: Policy Recommendations for Equity, Sustainability, and Impact.

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Milbank Quarterly

• Publication date

  2025-07-18

• Fields of study

  Medicine, Economics, Political Science

• Identifiers
  DOI 10.1111/1468-0009.70036PMID 40678955PMCID PMC12673170
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Understanding and Addressing Widening Racial Inequalities in Drug Overdose.

  2024cited by this paper
• Widening Racial Disparities in the US Overdose Epidemic.

  2024cited by this paper
• A simple heuristic for allocating opioid settlement funding to reduce overdose mortality in the United States

  2024cited by this paper
• Public Health Interventions and Overdose-Related Outcomes Among Persons With Opioid Use Disorder

  2024cited by this paper
• Simulating the Simultaneous Impact of Medication for Opioid Use Disorder and Naloxone on Opioid Overdose Death in Eight New York Counties

  2024cited by this paper
• Estimated Reductions in Opioid Overdose Deaths With Sustainment of Public Health Interventions in 4 US States

  2023cited by this paper
• The Opioid Settlements-Will the First Steps Be in the Right Direction?

  2023cited by this paper
• Racial and Ethnic Disparities in Drug Overdose Deaths in the US During the COVID-19 Pandemic

  2022cited by this paper
• Reducing opioid use disorder and overdose deaths in the United States: A dynamic modeling analysis

  2022cited by this paper
• State-Level Economic Costs of Opioid Use Disorder and Fatal Opioid Overdose — United States, 2017

  2021cited by this paper
• Pharmaceutical opioid marketing and physician prescribing behavior.

  2021cited by this paper
• Projected Estimates of Opioid Mortality After Community-Level Interventions

  2021cited by this paper
• Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US

  2020cited by this paper
• The Opioid/Overdose Crisis as a Dialectics of Pain, Despair, and One-Sided Struggle

  2020cited by this paper
• A Critical Review of the Social and Behavioral Contributions to the Overdose Epidemic

  2020cited by this paper
• Guiding industry settlements of opioid litigation

  2019cited by this paper
• Association between Opioid Prescribing in Medicare and Pharmaceutical Company Gifts by Physician Specialty

  2019cited by this paper
• Pharmaceutical payments to physicians may increase prescribing for opioids

  2019cited by this paper
• Association of Pharmaceutical Industry Marketing of Opioid Products to Physicians With Subsequent Opioid Prescribing

  2018cited by this paper
• Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016

  2018cited by this paper
• Drug Companies' Liability for the Opioid Epidemic.

  2017cited by this paper
• Industry Payments to Physicians for Opioid Products, 2013-2015

  2017cited by this paper
• Master Settlement Agreement (MSA) Spending and Tobacco Control Efforts

  2014cited by this paper
• The Master Settlement Agreement and its impact on tobacco use 10 years later: lessons for physicians about health policy making.

  2010cited by this paper
• The promotion and marketing of oxycontin: commercial triumph, public health tragedy.

  2009cited by this paper
• States' allocations of funds from the tobacco master settlement agreement.

  2005cited by this paper
• A major state tobacco tax increase, the master settlement agreement, and cigarette consumption: the California experience.

  2005cited by this paper
• The impact of the Master Settlement Agreement on cigarette consumption.

  2004cited by this paper

• No citing papers are available for this paper.